LLY - Eli Lilly and Company

NYSE - Nasdaq Real Time Price. Currency in USD
105.63
+1.27 (+1.22%)
As of 2:42PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close104.36
Open104.43
Bid105.66 x 800
Ask105.67 x 800
Day's Range104.31 - 105.92
52 Week Range73.69 - 105.92
Volume2,329,475
Avg. Volume3,647,906
Market Cap107.649B
Beta0.43
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateOct 23, 2018
Forward Dividend & Yield2.25 (2.21%)
Ex-Dividend Date2018-08-14
1y Target Est97.13
Trade prices are not sourced from all markets
  • Lilly (LLY) Hits 52-Week High, Can the Run Continue?
    Zacks4 hours ago

    Lilly (LLY) Hits 52-Week High, Can the Run Continue?

    Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Benzinga6 hours ago

    The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 16) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Eli Lilly And ...

  • Investopediayesterday

    Eli Lilly's Overbought Stock Poised to Fall 15%

    Eli Lilly and Co.'s ( LLY) stock has jumped by more than 16% since the middle of July and by nearly 24% in 2018. The stock is poised to plunge 15% in the coming weeks, based on technical analysis. Eli Lilly's stock broke out following better-than-expected quarterly results and guidance, rising above a long-term technical resistance level around $88.50.

  • A Look at the Performance of Bausch Health’s Ortho Dermatologics
    Market Realistyesterday

    A Look at the Performance of Bausch Health’s Ortho Dermatologics

    Bausch Health Companies’ (BHC) wholly-owned subsidiary Ortho Dermatologics generated revenue of $142.0 million in the second quarter compared to $162 million in the second quarter of 2017, reflecting a ~12% YoY (year-over-year) fall.

  • The Wall Street Journal2 days ago

    [$$] Karuna Appoints Steven Paul as CEO

    Karuna Pharmaceuticals Inc., which is developing treatments for schizophrenia and other neurological conditions, has appointed Chairman Steven Paul as chief executive.

  • What Does Nektar Therapeutics’ Valuation Trend Indicate?
    Market Realist2 days ago

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 

  • Elanco Animal Health Announces Pricing of $2.0 Billion of Senior Notes
    PR Newswire3 days ago

    Elanco Animal Health Announces Pricing of $2.0 Billion of Senior Notes

    Elanco will place the net proceeds of the Offering into escrow, to be released upon either the completion of its previously announced, anticipated initial public offering (IPO) or a special mandatory redemption, which would occur if the IPO does not take place, or Lilly otherwise determines that the IPO will not take place, by June 30, 2019. Elanco intends to pay the net proceeds of the Offering as part of the consideration to Lilly.

  • Analyzing Nektar Therapeutics’ Financial Performance
    Market Realist3 days ago

    Analyzing Nektar Therapeutics’ Financial Performance

    Nektar Therapeutics (NKTR) generated revenue of $1.09 billion in the second quarter compared to $34.59 million in the second quarter of 2017. 

  • Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018
    Market Realist3 days ago

    Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018

    In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.

  • Novo Nordisk’s Fast-Acting Insulins: A Performance Overview
    Market Realist3 days ago

    Novo Nordisk’s Fast-Acting Insulins: A Performance Overview

    In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.

  • Mylan Launches First Adcirca Generic, Stock Moves Up
    Market Realist4 days ago

    Mylan Launches First Adcirca Generic, Stock Moves Up

    Today, Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States. The drug is the first generic version of Eli Lilly’s (LLY) Adcirca (tadalafil) approved by the FDA.

  • Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?
    Market Realist4 days ago

    Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?

    Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.

  • Novo Nordisk: A Financial Overview after the First Half of 2018
    Market Realist4 days ago

    Novo Nordisk: A Financial Overview after the First Half of 2018

    Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.

  • Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings
    Zacks4 days ago

    Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings

    Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.

  • Eli Lilly Stock History
    Motley Fool7 days ago

    Eli Lilly Stock History

    Here's how this company became a biopharma giant, and what could be in store next for investors.

  • Analysts’ Recommendations for Pfizer on August 6
    Market Realist8 days ago

    Analysts’ Recommendations for Pfizer on August 6

    Analysts expect Pfizer’s (PFE) adjusted EPS to be $2.99 on revenue of $54.3 billion in 2018, a 3.4% rise compared to $52.5 billion in 2017. Analysts also expect a 10.9% rise in the company’s adjusted net income during 2018, mainly due to a fall in its selling, general, and administrative expenses as well as its lower research and development expenses as a percentage of its sales.

  • Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates
    Zacks8 days ago

    Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates

    Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.

  • A Look at Recent Developments at Pfizer
    Market Realist8 days ago

    A Look at Recent Developments at Pfizer

    Pfizer’s (PFE) Innovative Health business is focused on developing and commercializing medicines, vaccines, and consumer healthcare products, while its Essential Health business includes legacy brands and generic products, research and development, and its contract manufacturing business.

  • Eli Lilly Raised Its Non-GAAP Earnings Guidance for Fiscal 2018
    Market Realist9 days ago

    Eli Lilly Raised Its Non-GAAP Earnings Guidance for Fiscal 2018

    In Eli Lilly’s (LLY) second-quarter earnings conference call, the company raised its fiscal 2018 non-GAAP EPS guidance from the previously projected range of $5.10–$5.20 to $5.40–$5.50. If we consider the midpoint of the guidance range, the guidance implies a rise of 27% YoY (year-over-year) in the company’s non-GAAP EPS in fiscal 2018. Eli Lilly reduced its fiscal 2018 GAAP EPS guidance from the previously projected range of $4.52–$4.62 to $3.19–$3.29 due to higher charges associated with in-process research and development related to the acquisition of ARMO BioSciences.

  • Is Eli Lilly (LLY) a Great Dividend Play?
    Zacks9 days ago

    Is Eli Lilly (LLY) a Great Dividend Play?

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

  • Investopedia10 days ago

    Why Health Care Stocks Are Outshining The Techs

    Health care stocks have made a sharp break to the upside so far in the third quarter, leading the S&P 500 Index (SPX) and outpacing tech stocks in the process. As measured by both the S&P 500 Health Care Index and the Health Care Select Sector SPDR ETF ( XLV), health care stocks closed Monday just 1.8% below their record highs set in January. "Overall they look quite good," said Matt Maley, equity strategist at Miller Tabak, in an interview with  CNBC.

  • Merck and Its Peers: Analysts’ Recommendations in August
    Market Realist10 days ago

    Merck and Its Peers: Analysts’ Recommendations in August

    In its second-quarter earnings conference call, Merck (MRK) updated its revenue guidance range from the previous guidance of $41.8 billion–$43 billion to $42 billion–$42.8 billion. The updated guidance includes a favorable impact of mid-July foreign currency rates. The company also narrowed and increased its non-GAAP EPS guidance range from $4.16–$4.28 to $4.22–$4.30 despite an unfavorable impact of 100 basis points projected at mid-July foreign currency rates.

  • Pfizer Reports Revenue Growth in Q2 2018
    Market Realist10 days ago

    Pfizer Reports Revenue Growth in Q2 2018

    Pfizer (PFE) released its second-quarter earnings results on July 31. Pfizer surpassed Wall Street analysts’ consensus estimates for EPS and revenue. Pfizer’s top line increased 4% to ~$13.47 million in the second quarter, including a 2% rise in operating revenue and a 2% favorable impact of foreign exchange.

  • Q2 Earnings Drive Pharma ETFs Higher
    Zacks10 days ago

    Q2 Earnings Drive Pharma ETFs Higher

    The string of strong results pushed pharma ETFs higher, with the four funds posting positive returns over the past one month.

  • Investor's Business Daily11 days ago

    Does Bausch Face A Reckoning? 5 Key Issues To Look For In Its Earnings

    The name Valeant Pharmaceuticals might be in the dustbin, but Bausch Health Companies still faces an uphill earnings battle with investors, analysts say.